NERLYNX Drug Patent Profile

Which patents cover Nerlynx, and what generic alternatives are available?

Nerlynx is a drug marketed by Puma Biotech and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixteen patent family members in thirty-six countries.

The generic ingredient in NERLYNX is neratinib maleate. One supplier is listed for this compound. Additional details are available on the neratinib maleate profile page.

DrugPatentWatch^® Generic Entry Outlook for Nerlynx

Nerlynx was eligible for patent challenges on July 17, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 29, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (neratinib maleate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NERLYNX

International Patents:	216
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	23
Patent Applications:	4,019
Drug Prices:	Drug price information for NERLYNX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NERLYNX
What excipients (inactive ingredients) are in NERLYNX?	NERLYNX excipients list
DailyMed Link:	NERLYNX at DailyMed

See drug prices for NERLYNX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NERLYNX

Constraining patent/regulatory exclusivity:

7,399,865

NDA:

208051

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NERLYNX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 2
National Comprehensive Cancer Network	Phase 2
H. Lee Moffitt Cancer Center and Research Institute	Phase 2

See all NERLYNX clinical trials

Pharmacology for NERLYNX

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for NERLYNX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NERLYNX	Tablets	neratinib maleate	40 mg	208051	1	2021-07-19

US Patents and Regulatory Information for NERLYNX

NERLYNX is protected by twenty US patents.

This potential generic entry date is based on patent 7,399,865.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	8,518,446		Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	8,669,273
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	9,211,291
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	7,399,865		Y	Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	10,035,788
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	8,790,708		Y
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017		RX	Yes	Yes	9,630,946

Expired US Patents for NERLYNX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017	6,288,082
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051-001	Jul 17, 2017	7,982,043

International Patents for NERLYNX

See the table below for patents covering NERLYNX around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3088398	SELS DE MALEATE DE (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE ET LEURS FORMES CRISTALLINES (MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF)
Cyprus	1122330
Argentina	114143
European Patent Office	3000467
Israel	210616	שימוש בשילוב סינרגיסטי של נרטיניב וקפסיטבין להכנת תרופות (Use of a synergistic combination of neratinib and capecitabine in the manufacture of medicaments)
Japan	2018109071	（Ｅ）−Ｎ−｛４−［３−クロロ−４−（２−ピリジニルメトキシ）アニリノ］−３−シアノ−７−エトキシ−６−キノリニル｝−４−（ジメチルアミノ）−２−ブテンアミドのマレイン酸塩およびその結晶形態 (MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE, AND CRYSTALLINE FORMS THEREOF)
Argentina	076197

Supplementary Protection Certificates for NERLYNX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3000467	C20230025	Finland
4066821	CA 2025 00028	Denmark		PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180831
3000467	122023000045	Germany		PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180831
3000467	C202330029	Spain		PRODUCT NAME: NERATINIB; NATIONAL AUTHORISATION NUMBER: EU/1/18/1311; DATE OF AUTHORISATION: 20180831; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1311; DATE OF FIRST AUTHORISATION IN EEA: 20180831
4066821	C20250029	Finland
3000467	LUC00310	Luxembourg		PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904
3000467	PA2023520	Lithuania		PRODUCT NAME: NERATINIBAS; REGISTRATION NO/DATE: EU/1/18/1311 20230526

NERLYNX: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

NERLYNX (neratinib), a tyrosine kinase inhibitor, targets HER2-positive breast cancer. Its market performance is shaped by efficacy data, competitive landscape, and regulatory approvals. The drug's financial trajectory is a function of sales growth, patent exclusivity, and lifecycle management.

What is NERLYNX's Approval Status and Label Expansion?

NERLYNX received initial U.S. Food and Drug Administration (FDA) approval on July 17, 2017, for extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant taxane and trastuzumab-based HER2-directed systemic therapy [1]. This approval was based on the ExteNET trial, which demonstrated a statistically significant improvement in invasive disease-free survival (iDFS) [1].

A significant label expansion occurred on February 12, 2020, when the FDA approved NERLYNX for the treatment of adult patients with advanced HER2-positive breast cancer, whose disease has progressed despite prior HER2-directed therapy [2]. This broadened the drug's addressable patient population.

European Medicines Agency (EMA) approval followed on September 26, 2017, for extended adjuvant therapy in early-stage HER2-positive breast cancer patients who have completed prior trastuzumab-based adjuvant therapy [3].

What is the Competitive Landscape for NERLYNX?

The HER2-positive breast cancer market is competitive, with several approved therapies. Key competitors include:

• Tucatinib (TUKYSA): Approved for patients with advanced unresectable or metastatic HER2-positive breast cancer, including those who have received prior anti-HER2 treatment [4]. Tucatinib is often used in combination with trastuzumab and capecitabine.
• Trastuzumab (HERCEPTIN) and Pertuzumab (PERJETA): These are cornerstone therapies for HER2-positive breast cancer, used in various stages of the disease, often in combination with chemotherapy [5].
• Trastuzumab Emtansine (KADCYLA): An antibody-drug conjugate approved for HER2-positive metastatic breast cancer patients who have received prior trastuzumab and taxane therapy [6].
• Lapatinib (TYKERB): Another tyrosine kinase inhibitor used for HER2-positive breast cancer, typically in combination with capecitabine for patients with advanced or metastatic disease [7].

The competitive advantage of NERLYNX lies in its distinct mechanism of action, targeting multiple HER receptors, and its indication for extended adjuvant therapy, a niche not fully covered by all competitors. However, side effect profiles, particularly diarrhea, have influenced treatment sequencing and patient adherence [8].

What are NERLYNX's Clinical Trial Data Highlights?

The primary clinical trial supporting NERLYNX's initial approval was the Phase III ExteNET study [1]. This study randomized 1,421 patients to receive either NERLYNX or placebo for one year following adjuvant trastuzumab-based therapy.

• Primary Endpoint (iDFS): The study met its primary endpoint, demonstrating a 33% relative risk reduction in the rate of invasive breast cancer recurrence or death [1].
• iDFS at 2 Years: In the intent-to-treat population, iDFS at two years was 91.5% for NERLYNX and 87.3% for placebo (hazard ratio [HR] 0.70; 95% confidence interval [CI] 0.55-0.89; p=0.004) [1].
• Overall Survival (OS): While not statistically significant at the time of initial approval, subsequent analyses of ExteNET showed a trend towards improved OS in the intent-to-treat population [9].
• Adverse Events: The most common adverse events observed were diarrhea (92%), nausea (53%), and abdominal pain (36%) [1]. Diarrhea management strategies are crucial for patient tolerability.

The Phase III TROPIC-03 trial investigated NERLYNX in combination with trastuzumab and pertuzumab for first-line treatment of HER2-positive metastatic breast cancer, but did not meet its primary endpoint of progression-free survival (PFS) [10]. This outcome impacts the drug's potential in earlier lines of therapy for metastatic disease.

What is NERLYNX's Sales Performance and Financial Outlook?

NERLYNX is marketed by Puma Biotechnology, Inc. The drug's sales have shown a trajectory influenced by market adoption, competition, and strategic initiatives.

Year	Net Product Revenue (USD Millions)	Percentage Change
2018	66.0	N/A
2019	119.2	80.6%
2020	154.0	29.2%
2021	157.3	2.2%
2022	145.6	-7.4%
2023	136.6	-6.1%

Source: Puma Biotechnology, Inc. SEC Filings (10-K, 10-Q reports)

Analysis of Sales Trends:

• Initial Growth: The period from 2018 to 2020 demonstrated substantial growth, driven by the initial launch and subsequent label expansion for advanced disease.
• Stagnation and Decline: From 2021 onwards, sales have stagnated and begun to decline. This can be attributed to:
  • Increased Competition: The entry and established use of newer agents like Tucatinib.
  • Side Effect Management: Persistent challenges with managing diarrhea, impacting patient compliance and physician prescribing patterns.
  • Market Saturation: The HER2-positive early breast cancer adjuvant setting is a defined population.

Puma Biotechnology has focused on optimizing prescribing patterns, enhancing patient support programs, and exploring potential lifecycle management strategies. However, patent exclusivity is a critical factor for future revenue.

What are the Key Patent Expirations and Generic Competition Risks?

NERLYNX is protected by several U.S. patents. The most critical patents cover the compound itself and its methods of use.

• Composition of Matter Patent: U.S. Patent No. 7,402,604, with an expiration date of October 26, 2024 (subject to potential patent term adjustments). This patent is fundamental to the drug's existence.
• Method of Use Patents: Patents covering specific indications and treatment regimens, such as U.S. Patent No. 9,572,776 (Expiration: November 22, 2031) for extended adjuvant therapy and U.S. Patent No. 10,213,332 (Expiration: March 5, 2034) for the treatment of advanced HER2-positive breast cancer.

Generic Entry Risk:

The primary risk to NERLYNX's revenue stream is the eventual loss of market exclusivity due to patent expirations. The composition of matter patent expiring in late 2024 is a significant milestone. Generic manufacturers can file Abbreviated New Drug Applications (ANDAs) to challenge existing patents through Paragraph IV certifications.

• ANDA Filings and Litigation: Puma Biotechnology has actively defended its patents. Litigation surrounding Paragraph IV challenges is common in the pharmaceutical industry and can lead to earlier generic entry if successful for the challenger.
• Impact of Generic Entry: The introduction of generic versions of NERLYNX will likely lead to a significant decrease in its market share and pricing power, a common phenomenon across the pharmaceutical sector.

Strategic Considerations for Patent Expirations:

• Extended Release Formulations: Development of new formulations with extended patent life.
• New Indications: Seeking approval for novel uses or patient populations.
• Combination Therapies: Investigating NERLYNX in combination with other agents that might lead to new patentable claims.
• Life Cycle Management: Strategies to maximize revenue from existing patents and prepare for the transition to generic competition.

What is the Impact of Real-World Evidence (RWE) and Post-Marketing Studies?

Real-world evidence and post-marketing studies are crucial for understanding NERLYNX's long-term safety and effectiveness in broader patient populations beyond clinical trial participants.

• Diarrhea Management in Real-World Settings: Studies aim to evaluate the effectiveness of various management strategies for diarrhea, a dose-limiting toxicity, and identify predictors of severe events [11]. Improved diarrhea management protocols could enhance patient adherence and broaden physician comfort.
• Treatment Patterns: RWE can shed light on how NERLYNX is sequenced in clinical practice, especially in the advanced setting, and its comparative effectiveness against other approved therapies in unselected patient groups.
• Subgroup Analyses: Post-marketing data can provide insights into NERLYNX's efficacy and safety in specific patient subgroups (e.g., elderly patients, patients with specific comorbidities) that may have been underrepresented in pivotal trials.

The collection and analysis of RWE are vital for confirming the drug's value proposition and informing clinical decision-making. Positive RWE can support continued market access and reimbursement.

What are the Regulatory Considerations and Future Outlook?

Regulatory bodies continuously monitor drug safety and efficacy through post-marketing surveillance.

• Pharmacovigilance: Ongoing monitoring for adverse events is a standard requirement. Any emerging safety signals could lead to label updates or restrictions.
• Label Updates: As new data emerges from ongoing studies or RWE, regulatory agencies may require label updates to reflect the latest scientific understanding of the drug's benefits and risks.
• Market Access and Reimbursement: Payers (insurance companies, government health programs) evaluate cost-effectiveness and clinical utility. Real-world data and evidence of improved patient outcomes are critical for maintaining favorable reimbursement status.

The future outlook for NERLYNX will depend on its ability to maintain its market position against evolving competition, manage its side effect profile effectively through improved patient management, and navigate the upcoming patent cliff. Puma Biotechnology's strategic decisions regarding R&D, business development, and intellectual property will be paramount.

Key Takeaways

• NERLYNX is approved for extended adjuvant and advanced HER2-positive breast cancer, with its initial approval in 2017.
• The competitive landscape includes established therapies like trastuzumab, pertuzumab, and newer agents such as tucatinib.
• NERLYNX's sales peaked in 2020 and have since experienced stagnation and decline, influenced by competition and tolerability issues.
• The primary composition of matter patent for NERLYNX expires in October 2024, posing a significant risk of generic competition.
• Real-world evidence is crucial for understanding long-term outcomes and supporting market access, particularly regarding diarrhea management.

Frequently Asked Questions

1. When did NERLYNX first receive FDA approval? NERLYNX first received FDA approval on July 17, 2017.
2. What is the primary patent expiration date for NERLYNX's composition of matter? The primary composition of matter patent is expected to expire on October 26, 2024.
3. What is the most common significant side effect associated with NERLYNX? Diarrhea is the most common and often dose-limiting side effect of NERLYNX.
4. Has NERLYNX been approved for any indications beyond breast cancer? Currently, NERLYNX is approved solely for HER2-positive breast cancer in the U.S. and Europe.
5. What is Puma Biotechnology's strategy for addressing the upcoming patent expiration? Puma Biotechnology has historically defended its intellectual property through litigation and may explore life cycle management strategies, although specific future plans are subject to ongoing business strategy.

Citations

[1] Baselga, J., et al. (2016). Neratinib versus placebo in extension therapy of HER2-positive breast cancer. New England Journal of Medicine, 375(3), 215-226.

[2] U.S. Food and Drug Administration. (2020, February 12). FDA approves neratinib for extended adjuvant treatment of HER2-overexpressed/amplified, node-positive early stage breast cancer. FDA News Release.

[3] European Medicines Agency. (2017, September 26). European Commission grants marketing authorisation for Nerlynx® (neratinib). [Press Release].

[4] U.S. Food and Drug Administration. (2020, April 17). FDA approves tucatinib for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer. FDA News Release.

[5] Slamon, D. J., et al. (2001). Addition of chemotherapy to tamoxifen in breast cancer with HER-2-neu positivity, and the effect of tamoxifen with or without chemotherapy. New England Journal of Medicine, 344(11), 787-792.

[6] Verma, S., et al. (2012). Trastuzumab emtansine versus taxane plus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a phase 3, open-label, randomised trial. The Lancet Oncology, 13(9), 969-979.

[7] Geyer, C. E., et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced or metastatic breast cancer. New England Journal of Medicine, 355(26), 2733-2744.

[8] Wildiers, H., et al. (2018). Managing diarrhea associated with neratinib: recommendations from an expert panel. Annals of Oncology, 29(6), 1309-1316.

[9] Puma Biotechnology, Inc. (2021). Investor Relations Presentation.

[10] Deeks, S. G., et al. (2017). Phase III Trial of Neratinib Plus Trastuzumab and Pertuzumab for First-Line Treatment of HER2-Positive Metastatic Breast Cancer (TROPIC-03). Journal of Clinical Oncology, 35(15_suppl), 1039-1039.

[11] Saura, C., et al. (2020). Real-world evidence on the efficacy and safety of neratinib in patients with HER2-positive breast cancer: the NANAR study. Clinical Breast Cancer, 20(5), e565-e575.